Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma
Nicole M. Naranjo Anne Kennedy Anna Testa Cecilia E. Verrillo Adrian D. Altieri Rhonda Kean D. Craig Hooper Jindan Yu Jonathan Zhao Oliver Abinader Maxwell W. Pickles Adam Hawkins William K. Kelly Ramkrishna Mitra Lucia R. Languino a Prostate Cancer Discovery and Development Program,Thomas Jefferson University,Philadelphia,PA,USAb Department of Pharmacology,Physiology and Cancer Biology,Thomas Jefferson University,Philadelphia,PA,USAc Department of Neurological Surgery,Thomas Jefferson University,Philadelphia,PA,USAd Department of Urology,Emory University School of Medicine,Atlanta,GA,USAe Department of Human Genetics,Emory University School of Medicine,Atlanta,GA,USAf Division of Biostatistics and Bioinformatics,Department of Pharmacology,Physiology and Cancer Biology,Thomas Jefferson University,Philadelphia,PA,USAg Department of Medical Oncology,Thomas Jefferson University,Philadelphia,PA,USA
DOI: https://doi.org/10.1080/15384047.2024.2364433
2024-06-27
Cancer Biology & Therapy
Abstract:Prostate cancer has heterogeneous growth patterns, and its prognosis is the poorest when it progresses to a neuroendocrine phenotype. Using bioinformatic analysis, we evaluated RNA expression of neuroendocrine genes in a panel of five different cancer types: prostate adenocarcinoma, breast cancer, kidney chromophobe, kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma. Our results show that specific neuroendocrine genes are significantly dysregulated in these tumors, suggesting that they play an active role in cancer progression. Among others, synaptophysin (SYP), a conventional neuroendocrine marker, is upregulated in prostate adenocarcinoma (PRAD) and breast cancer (BRCA). Our analysis shows that SYP is enriched in small extracellular vesicles (sEVs) derived from plasma of PRAD patients, but it is absent in sEVs derived from plasma of healthy donors. Similarly, classical sEV markers are enriched in sEVs derived from plasma of prostate cancer patients, but weakly detectable in sEVs derived from plasma of healthy donors. Overall, our results pave the way to explore new strategies to diagnose these diseases based on the neuroendocrine gene expression in patient tumors or plasma sEVs.
oncology